These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 2898970)

  • 1. Simultaneous modeling of pharmacokinetics and pharmacodynamics: an improved algorithm.
    Verotta D; Sheiner LB
    Comput Appl Biosci; 1987 Nov; 3(4):345-9. PubMed ID: 2898970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.
    Unadkat JD; Bartha F; Sheiner LB
    Clin Pharmacol Ther; 1986 Jul; 40(1):86-93. PubMed ID: 3720181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model.
    Fuseau E; Sheiner LB
    Clin Pharmacol Ther; 1984 Jun; 35(6):733-41. PubMed ID: 6329584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volterra series in pharmacokinetics and pharmacodynamics.
    Verotta D
    J Pharmacokinet Pharmacodyn; 2003 Oct; 30(5):337-62. PubMed ID: 14977164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.
    Derendorf H; Meibohm B
    Pharm Res; 1999 Feb; 16(2):176-85. PubMed ID: 10100300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Models for evaluating the pharmacokinetics and pharmacodynamics for β-blockers.
    Höcht C; Bertera FM; Del Mauro JS; Taira CA
    Expert Opin Drug Metab Toxicol; 2014 Apr; 10(4):525-41. PubMed ID: 24593316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
    Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect pharmacodynamic response models do not require any parametric pharmacokinetic model to be fitted to effect-time data.
    Piotrovsky VK
    Methods Find Exp Clin Pharmacol; 1997 Dec; 19(10):723-9. PubMed ID: 9542723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.
    Gumbleton M; Oie S; Verotta D
    Br J Clin Pharmacol; 1994 Nov; 38(5):389-400. PubMed ID: 7893578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inverse PK/PD: estimation and differentiation of bioavailability from effect kinetics--observations with beta-adrenoceptor antagonists.
    De Mey C
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):453-7. PubMed ID: 9352395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.
    Ayyar VS; Jusko WJ
    Pharmacol Rev; 2020 Apr; 72(2):414-438. PubMed ID: 32123034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol.
    Bertera FM; Di Verniero CA; Mayer MA; Bramuglia GF; Taira CA; Höcht C
    J Pharmacol Toxicol Methods; 2009; 59(1):13-20. PubMed ID: 18973819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.
    Bauer RJ; Guzy S; Ng C
    AAPS J; 2007 Mar; 9(1):E60-83. PubMed ID: 17408237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing convergence of Markov chain Monte Carlo simulations in hierarchical Bayesian models for population pharmacokinetics.
    Dodds MG; Vicini P
    Ann Biomed Eng; 2004 Sep; 32(9):1300-13. PubMed ID: 15493516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programming of a flexible computer simulation to visualize pharmacokinetic-pharmacodynamic models.
    Lötsch J; Kobal G; Geisslinger G
    Int J Clin Pharmacol Ther; 2004 Jan; 42(1):15-22. PubMed ID: 14756382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol.
    Liu XY; Wang BJ; Yuan GY; Guo RC
    Yao Xue Xue Bao; 2009 Apr; 44(4):406-11. PubMed ID: 19545060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity.
    Kirch W; Milferstädt S; Halabi A; Rocher I; Efthymiopoulos C; Jung L
    Cardiovasc Drugs Ther; 1990 Apr; 4(2):487-91. PubMed ID: 1981019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
    Zhang L; Beal SL; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):387-404. PubMed ID: 15000421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.
    Minto CF; Schnider TW; Gregg KM; Henthorn TK; Shafer SL
    Anesthesiology; 2003 Aug; 99(2):324-33. PubMed ID: 12883405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.